Personalis, Inc. (PSNL)

Market Cap	318.63M
Revenue (ttm)	84.61M
Net Income (ttm)	-81.28M
Shares Out	88.26M
EPS (ttm)	-1.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,256,982
Open	3.780
Previous Close	3.840
Day's Range	3.600 - 3.790
52-Week Range	1.135 - 7.200
Beta	1.73
Analysts	Strong Buy
Price Target	7.80 (+116.07%)
Earnings Date	May 7, 2025

About PSNL

Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal res...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Jun 20, 2019
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: PSNL
• Website: https://www.personalis.com

Financial Performance

In 2024, Personalis's revenue was $84.61 million, an increase of 15.15% compared to the previous year's $73.48 million. Losses were -$81.28 million, -24.94% less than in 2023.

Analyst Forecast

According to 5 analysts, the average rating for PSNL stock is "Strong Buy." The 12-month stock price forecast is $7.8, which is an increase of 116.07% from the latest price.

Price Target

$7.8

(116.07% upside)

Analyst Consensus: Strong Buy